EP 3407918 A4 20190904 - METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
Title (en)
METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION
Title (de)
VERFAHREN UND ZUSAMMENSETZUNGEN ZUR RNA-GEFÜHRTEN BEHANDLUNG VON HIV-INFEKTIONEN
Title (fr)
MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT GUIDÉ PAR ARN D'UNE INFECTION PAR LE VIH
Publication
Application
Priority
- US 201662286575 P 20160125
- US 2017014667 W 20170124
Abstract (en)
[origin: WO2017132112A1] A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus..
IPC 8 full level
A61K 38/46 (2006.01); A61K 48/00 (2006.01); A61P 31/12 (2006.01); A61P 31/18 (2006.01); C12N 15/63 (2006.01)
CPC (source: EP US)
A61K 31/711 (2013.01 - EP US); A61P 31/18 (2017.12 - EP US); C12N 9/22 (2013.01 - EP US); C12N 15/102 (2013.01 - EP US); C12N 15/1132 (2013.01 - US); C12N 15/70 (2013.01 - US); C12N 15/86 (2013.01 - US); C12Q 1/703 (2013.01 - US); C12N 2310/20 (2017.04 - US); C12N 2740/16021 (2013.01 - EP US)
Citation (search report)
- [X] WO 2015031775 A1 20150305 - UNIV TEMPLE [US]
- [Y] KAMEL KHALILI ET AL: "Genome editing strategies: potential tools for eradicating HIV-1/AIDS", JOURNAL OF NEUROVIROLOGY, vol. 21, no. 3, 26 February 2015 (2015-02-26), GB, pages 310 - 321, XP055534280, ISSN: 1355-0284, DOI: 10.1007/s13365-014-0308-9
- [Y] HSIN-KAI LIAO ET AL: "Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells", NATURE COMMUNICATIONS, vol. 6, 10 March 2015 (2015-03-10), GB, pages 6413, XP055278134, ISSN: 2041-1723, DOI: 10.1038/ncomms7413
- [Y] HIROTAKA EBINA ET AL: "Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus", SCIENTIFIC REPORTS, vol. 3, no. 1, 26 August 2013 (2013-08-26), XP055548923, DOI: 10.1038/srep02510
- [XP] RAFAL KAMINSKI ET AL: "Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing", SCIENTIFIC REPORTS, vol. 6, 4 March 2016 (2016-03-04), pages 22555, XP055321605, DOI: 10.1038/srep22555
- [XP] R KAMINSKI ET AL: "Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study", GENE THERAPY, vol. 23, no. 8 & 9, 19 May 2016 (2016-05-19), GB, pages 690 - 695, XP055534211, ISSN: 0969-7128, DOI: 10.1038/gt.2016.41
- See references of WO 2017132112A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2017132112 A1 20170803; AU 2017211062 A1 20180607; CA 3011874 A1 20170803; CN 108883201 A 20181123; EP 3407918 A1 20181205; EP 3407918 A4 20190904; JP 2019506156 A 20190307; RU 2018130640 A 20200225; RU 2018130640 A3 20200225; US 2019032057 A1 20190131
DOCDB simple family (application)
US 2017014667 W 20170124; AU 2017211062 A 20170124; CA 3011874 A 20170124; CN 201780007643 A 20170124; EP 17744745 A 20170124; JP 2018537650 A 20170124; RU 2018130640 A 20170124; US 201716072589 A 20170124